Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Rohit Dhall

CredentialsCertified Physician Executive
MD
TitleDepartment Chairperson
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentNeurology, College of Medicine
DivisionNeurology Faculty
Address501 Jack Stephens Drive
Mail Slot # 500
Little Rock AR 72205
Phone501-686-7236
ORCID ORCID Icon0000-0001-9436-1920 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My clinical expertise in diagnosis and management of Neurodegenerative disorders, including parkinsonism, dementias, dystonia and tremor. My clinical research focuses on developing novel diagnostics and therapeutics, and developing and improving programs delivering care to people living with neurological illness.

    In addition to serving as Department Chair of Neurology, I direct UAMS' Parkinson Foundation Comprehensive Care Center, and CurePSP Center of Care, and co-direct the Multiple Systems Atrophy Center of Excellence at UAMS.


    Collapse Biography 
    Collapse Leadership and Administrative Roles
    Chair Department of Neurology

    Medical Director, Clinical Trials Innovation Unit

    Director, Parkinson Foundation Comprehensive Care Center

    Director of CurePSP Center of Care at UAMS

    Collapse education and training
    All India Institute of Medical Sciences, New Delhi, IndiaMBBS (MD)12/2000Medicine, Surgery
    Univ. of Texas at Houston, School of Public Health, Houston, TXMSPH12/2008Epidemiology
    Univ. of Alabama at Birmingham, Birmingham, ALResidency training07/2007Neurology
    Univ. of Alabama at Birmingham, Birmingham, ALFellowship Training07/2009Movement Disorders and Deep Brain Stimulation
    American Association of Physician LeadersCertified Physician Executive11/2019Physician Leadership
    Harvard T.H. Chan School of Public Health Executive and Continuing Professional Education, Boston, MANA02/2024Program for Chairs of Clinical Services
    Univ. of Texas at Houston, Houston, TXNA06/2003Medicine Internship
    Collapse awards and honors
    2011 - 2021Elected by his peers for inclusion in Best Doctors in America®, Best Doctors Inc
    2021 - 2024Elected by his peers for inclusion in Top Doctors ® , Castle Connolly
    2021 - 2022Outstanding Mentor Award for educating and mentoring Geriatrics fellows , UAMS Institute on Aging
    2023 - 2024Red Sash Award for Medical Student Education, Univ. of Arkansas for Medical Sciences

    Collapse Teaching 

    Collapse Research 
    Collapse research activities and funding
    25-HCDA     (DHALL, ROHIT)May 1, 2025 - Apr 30, 2028
    ALS Association
    ALS Hoffman Clinic Development Program
    Role: Principal Investigator
    25-HCDA-004     (DHALL, ROHIT)May 1, 2025 - Apr 30, 2028
    ALS Association
    ALS Hoffman Clinic Development Program
    Role: Principal Investigator
    IPX203     (DHALL, ROHIT)Feb 10, 2025 - Feb 9, 2035
    Amneal Pharmaceuticals - Pass Through: Syneos Health
    Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease Patients (IRB 298113)
    Role: Principal Investigator
    IPX203-401-23     (DHALL, ROHIT)Feb 10, 2025 - Feb 9, 2035
    Amneal Pharmaceuticals - Pass Through: Syneos Health
    Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease Patients (IRB 298113)
    Role: Principal Investigator
    PF-CCC     (DHALL, ROHIT)Dec 1, 2024 - Nov 30, 2026
    Parkinson's Foundation
    Parkinson’s Foundation 2025-26 Global Care Network Award
    Role: Principal Investigator
    PF-CCC-1431769     (DHALL, ROHIT)Dec 1, 2024 - Nov 30, 2026
    Parkinson's Foundation
    Parkinson’s Foundation 2025-26 Global Care Network Award
    Role: Principal Investigator
    SAGE     (DHALL, ROHIT)May 1, 2024 - Apr 30, 2034
    Sage Therapeutics - Pass Through: PAREXEL International LLC
    A Phase 3, Multicenter, Open-Label Safety Study to Evaluate the Long-Term Safety and Tolerability of SAGE-718 in Participants with Huntington's Disease (IRB 276546)
    Role: Principal Investigator
    SAGE-718     (DHALL, ROHIT)May 1, 2024 - Apr 30, 2034
    Sage Therapeutics - Pass Through: PAREXEL International LLC
    A Phase 3, Multicenter, Open-Label Safety Study to Evaluate the Long-Term Safety and Tolerability of SAGE-718 in Participants with Huntington's Disease (IRB 276546)
    Role: Principal Investigator
    PF-CCC-1260184     (DHALL, ROHIT)Dec 1, 2023 - Nov 30, 2024
    Parkinson's Foundation
    Parkinson’s Foundation CCC
    Role: Principal Investigator
    PF-COE-AC     (DHALL, ROHIT)Jul 1, 2023 - Nov 30, 2023
    Parkinson's Foundation
    Parkinson’s Foundation Center Bridge Funding Grant
    Role: Principal Investigator
    PF-COE-AC-1275661     (DHALL, ROHIT)Jul 1, 2023 - Nov 30, 2023
    Parkinson's Foundation
    Parkinson’s Foundation Center Bridge Funding Grant
    Role: Principal Investigator
    IkT     (DHALL, ROHIT)Dec 16, 2022 - Dec 15, 2032
    Inhibikase Therapeutics, Inc. - Pass Through: IQVIA, Inc.
    A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease (IRB 274673)
    Role: Principal Investigator
    IkT-148009-201     (DHALL, ROHIT)Dec 16, 2022 - Dec 15, 2032
    Inhibikase Therapeutics, Inc. - Pass Through: IQVIA, Inc.
    A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease (IRB 274673)
    Role: Principal Investigator
    PD0053     (DHALL, ROHIT)Sep 13, 2022 - Sep 12, 2032
    UCB Biopharma - Pass Through: PAREXEL International LLC
    A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants with Early Parkinson's Disease (IRB 274317)
    Role: Principal Investigator
    C25304     (DHALL, ROHIT)Aug 25, 2022 - Aug 24, 2032
    Huntington Study Group
    Development of the Virtual Unified Huntington Disease Rating Scale (vUHDRS™) (IRB 274554)
    Role: Principal Investigator
    CLR     (DHALL, ROHIT)Aug 15, 2022 - Aug 14, 2032
    Sun Pharma Advanced Research Company Limited (SPARC) - Pass Through: Labcorp
    A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects with Early Parkinson's Disease (IRB 273929)
    Role: Principal Investigator
    CLR-18-06     (DHALL, ROHIT)Aug 15, 2022 - Aug 14, 2032
    Sun Pharma Advanced Research Company Limited (SPARC) - Pass Through: Labcorp
    A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects with Early Parkinson's Disease (IRB 273929)
    Role: Principal Investigator
    C24162     (DHALL, ROHIT)Jul 14, 2022 - Jul 13, 2032
    Alexion Pharmaceuticals - Pass Through: PPD Investigator Services, LLC
    A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis (IRB 273880)
    Role: Principal Investigator
    ABP     (DHALL, ROHIT)Oct 8, 2021 - Oct 7, 2031
    AEON Biopharma, Inc. - Pass Through: PPD Investigator Services, LLC
    A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia (IRB 262548)
    Role: Principal Investigator
    ABP-19000     (DHALL, ROHIT)Oct 8, 2021 - Oct 7, 2031
    AEON Biopharma, Inc. - Pass Through: PPD Investigator Services, LLC
    A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia (IRB 262548)
    Role: Principal Investigator
    CVL     (DHALL, ROHIT)Apr 22, 2021 - Jun 17, 2031
    Cerevel Therapeutics, LLC - Pass Through: Syneos Health
    58 Week Open-label Trial of Tavapadon in Parkinson's Disease (TemPO-4 Trial) (IRB 262509)
    Role: Principal Investigator
    CVL-751-PD-004     (DHALL, ROHIT)Apr 22, 2021 - Jun 17, 2031
    Cerevel Therapeutics, LLC - Pass Through: Syneos Health
    58 Week Open-label Trial of Tavapadon in Parkinson's Disease (TemPO-4 Trial) (IRB 262509)
    Role: Principal Investigator
    ND0612     (DHALL, ROHIT)Mar 3, 2021 - Mar 24, 2031
    NeuroDerm, Ltd. - Pass Through: Syneos Health
    A Multicenter, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison...(260930)
    Role: Principal Investigator
    ND0612-317     (DHALL, ROHIT)Mar 3, 2021 - Mar 24, 2031
    NeuroDerm, Ltd. - Pass Through: Syneos Health
    A Multicenter, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison...(260930)
    Role: Principal Investigator
    M15-736     (DHALL, ROHIT)Sep 18, 2020
    AbbVie Inc
    No FP attached
    Role: Principal Investigator
    CVL-751-PD-001     (DHALL, ROHIT)Sep 10, 2020 - Aug 26, 2030
    Cerevel Therapeutics, LLC - Pass Through: Syneos Health
    A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)
    Role: Principal Investigator
    ALXN1210-MG     (DHALL, ROHIT)Sep 9, 2020
    Alexion Pharmaceuticals - Pass Through: Syneos Health
    No FP attached
    Role: Principal Investigator
    ALXN1210-MG-306     (DHALL, ROHIT)Sep 9, 2020
    Alexion Pharmaceuticals - Pass Through: Syneos Health
    No FP attached
    Role: Principal Investigator
    NLY01-PD-1,     (DHALL, ROHIT)Jun 11, 2020 - Jun 10, 2030
    Neuraly - Pass Through: Rho, Inc
    No FP attached
    Role: Principal Investigator
    IPX203-B16-03     (DHALL, ROHIT)Dec 9, 2019 - Dec 10, 2029
    Syneos Health
    No FP attached
    Role: Principal Investigator
    Study 003     (DHALL, ROHIT)Oct 25, 2019 - Oct 29, 2024
    Global Kinetics Corporation Ltd.
    No FP attached
    Role: Principal Investigator
    Study003     (DHALL, ROHIT)Oct 25, 2019 - Oct 29, 2024
    Global Kinetics Corporation Ltd.
    No FP attached
    Role: Principal Investigator
    IPX203-B16-02     (DHALL, ROHIT)May 15, 2019
    Impax Laboratories, Inc.
    No FP attached
    Role: Principal Investigator
    IRB # 228403     (DHALL, ROHIT)Jan 8, 2019
    Cala Health, Inc
    PROSPECT: Prospective Study for Symptomatic Relief of ET with Cala Therapy (IRB 228403)
    Role: Principal Investigator
    IRB#228403     (DHALL, ROHIT)Jan 8, 2019
    Cala Health, Inc
    PROSPECT: Prospective Study for Symptomatic Relief of ET with Cala Therapy (IRB 228403)
    Role: Principal Investigator
    P2B001     (DHALL, ROHIT)Aug 16, 2018 - Aug 15, 2028
    Pharma Two B - Pass Through: Pharmaceutical Research Associates, Inc.
    No FP attached
    Role: Principal Investigator
    P2B001-003     (DHALL, ROHIT)Aug 16, 2018 - Aug 15, 2028
    Pharma Two B - Pass Through: Pharmaceutical Research Associates, Inc.
    No FP attached
    Role: Principal Investigator
    TOZ-CL06     (DHALL, ROHIT)Aug 8, 2017
    Biotie Therapies Inc.
    A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa- Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off”
    Role: Principal Investigator
    RVT-102-2003     (DHALL, ROHIT)Jul 28, 2017
    Axovant Sciences, Ltd.
    An open-label study of nelotanserin in patients with Lewy body dementia who have frequent visual hallucinations or REM sleep behaviors
    Role: Principal Investigator
    M15     (VAN RHEE, FRITS)May 30, 2017
    AbbVie Inc
    No FP attached
    Role: Principal Investigator
    RVT     (DHALL, ROHIT)May 17, 2017
    Axovant Sciences, Ltd.
    No FP attached
    Role: Principal Investigator
    RVT-102-2002     (DHALL, ROHIT)May 17, 2017
    Axovant Sciences, Ltd.
    No FP attached
    Role: Principal Investigator
    IPX203-B16     (DHALL, ROHIT)Mar 29, 2017
    Impax Laboratories, Inc.
    A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects with Advanced Parkinson’s Disease 205998
    Role: Principal Investigator
    IPX203-B16-01     (DHALL, ROHIT)Mar 29, 2017
    Impax Laboratories, Inc.
    A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects with Advanced Parkinson’s Disease 205998
    Role: Principal Investigator

    Collapse Outreach 

    Collapse Bibliographic 
    Collapse additional bibliographic sources
    The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Bruno MK, Dhall R, Duquette A, Haq IU, Honig LS, Lamotte G, Mari Z, McFarland NR, Montaser-Kouhsari L, Rodriguez-Porcel F, Shurer J, Siddiqui J, Spears CC, Wills AA, Diaz K, Golbe LI. A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders: A Consensus Statement. Neurol Clin Pract. 2024 Dec; 14(6):e200345. PMID: 39185098.
      View in: PubMed
    2. Lola Cook, Jennifer Verbrugge, Tae-Hwi Schwantes-An, Jeanine Schulze, Tatiana Foroud, Anne Hall, Karen S Marder, Ignacio F Mata, Niccolò E Mencacci, Martha A Nance, Michael A Schwarzschild, Tanya Simuni, Susan Bressman, Anne-Marie Wills, Hubert H Fernandez, Irene Litvan, Kelly E Lyons, Holly A Shill, Carlos Singer, Thomas F Tropea, Nora Vanegas Arroyave, Janfreisy Carbonell, Rossy Cruz Vicioso, Linn Katus, Joseph F Quinn, Priscila D Hodges, Yan Meng, Samuel P Strom, Cornelis Blauwendraat, Katja Lohmann, Cynthia Casaceli, Shilpa C Rao, Kamalini Ghosh Galvelis, Anna Naito, James C Beck, Roy N Alcalay, on behalf of the Parkinson’s Foundation and Parkinson Study Group PD GENEration investigators. Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study. Brain. 2024; 147(8):2668–2679.
      View Publication
    3. Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH, Kieburtz K, LeWitt PA, Lopez-Manzanares L, Olanow CW, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Lopes N, Sasson N, Case R, Rascol O. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol. 2024 May; 23(5):465-476. PMID: 38499015.
      View in: PubMed
    4. McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, St Hiliare MH, Shprecher D, Lee S, Dawson TM, Roschke V, Kieburtz K. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024 01; 23(1):37-45. PMID: 38101901.
      View in: PubMed
    5. Espay AJ, Hauser RA, Dhall R, Thakkar S, Cloud L, Zeitlin L, Banisadr G, Fisher S, Visser H. Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study. Mov Disord. 2024 Feb; 39(2):428-432. PMID: 38111267.
      View in: PubMed
    6. Olanow CW, Hauser RA, Burdick DJ, Dhall R, de Marcaida JA, Gil RA, Kreitzman DL, Elmer LW, McGarry A, Kieburtz K. A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease. Mov Disord. 2024 Feb; 39(2):350-359. PMID: 37886872.
      View in: PubMed
    7. Elberson B, Scott H, Dhall R, Petersen E. Impedance trend from a symptomatic perielectrode cystic cavity following deep brain stimulation: illustrative case. J Neurosurg Case Lessons. 2023 Sep 18; 6(12). PMID: 37756484.
      View in: PubMed
    8. Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023 06; 22(6):494-504. PMID: 37210099.
      View in: PubMed
    9. LeWitt P, Ellenbogen A, Burdick D, Gunzler S, Gil R, Dhall R, Banisadr G, D'Souza R. Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation. Clin Park Relat Disord. 2023; 8:100197. PMID: 37181100.
      View in: PubMed
    10. Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM. The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study. CNS Drugs. 2022 11; 36(11):1207-1216. PMID: 36242718.
      View in: PubMed
    11. Ojukwu DI, Wang AR, Hornbeck TS, Lim EA, Sharrard J, Dhall R, Buch VP, Halpern CH. Conversion to Hybrid Deep Brain Stimulation System to Enable Multi-Contact Fractionation Can be Therapeutic. Mov Disord. 2022 06; 37(6):1321-1323. PMID: 35393689.
      View in: PubMed
    12. Pfeifer KJ, Cook AJ, Yankulova JK, Mortimer BJP, Erickson-DiRenzo E, Dhall R, Montaser-Kouhsari L, Tass PA. Clinical Efficacy and Dosing of Vibrotactile Coordinated Reset Stimulation in Motor and Non-motor Symptoms of Parkinson's Disease: A Study Protocol. Front Neurol. 2021; 12:758481. PMID: 34867742.
      View in: PubMed
    13. Glover A, Pillai L, Dhall R, Virmani T. Olfactory Deficits in the Freezing of Gait Phenotype of Parkinson's Disease. Front Neurol. 2021; 12:656379. PMID: 34456839.
      View in: PubMed
    14. Bluett B, Pantelyat AY, Litvan I, Ali F, Apetauerova D, Bega D, Bloom L, Bower J, Boxer AL, Dale ML, Dhall R, Duquette A, Fernandez HH, Fleisher JE, Grossman M, Howell M, Kerwin DR, Leegwater-Kim J, Lepage C, Ljubenkov PA, Mancini M, McFarland NR, Moretti P, Myrick E, Patel P, Plummer LS, Rodriguez-Porcel F, Rojas J, Sidiropoulos C, Sklerov M, Sokol LL, Tuite PJ, VandeVrede L, Wilhelm J, Wills AA, Xie T, Golbe LI. Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. Front Neurol. 2021; 12:694872. PMID: 34276544.
      View in: PubMed
    15. Zavala B, Mirzadeh Z, Chen T, Lambert M, Chapple KM, Dhall R, Ponce FA. Electrophysiologic Mapping for Target Acquisition in Deep Brain Stimulation May Become Unnecessary in the Era of Intraoperative Imaging. World Neurosurg. 2021 08; 152:e51-e61. PMID: 33905908.
      View in: PubMed
    16. Pfeifer KJ, Kromer JA, Cook AJ, Hornbeck T, Lim EA, Mortimer BJP, Fogarty AS, Han SS, Dhall R, Halpern CH, Tass PA. Coordinated Reset Vibrotactile Stimulation Induces Sustained Cumulative Benefits in Parkinson's Disease. Front Physiol. 2021; 12:624317. PMID: 33889086.
      View in: PubMed
    17. Virmani T, Glover A, Pillai L, Lotia M, Dhall R. Utility of objective gait measures in levodopa-unresponsive freezing in Parkinson's. Clin Case Rep. 2021 Mar; 9(3):1072-1077. PMID: 33768785.
      View in: PubMed
    18. Isaacson SH, Peckham E, Tse W, Waln O, Way C, Petrossian MT, Dahodwala N, Soileau MJ, Lew M, Dietiker C, Luthra N, Agarwal P, Dhall R, Morgan J, Calakos N, Zesiewicz TA, Shamim EA, Kumar R, LeWitt P, Shill HA, Simmons A, Pagan FL, Khemani P, Tate J, Maddux B, Luo L, Ondo W, Hallett M, Rajagopal A, Chidester P, Rosenbluth KH, Delp SL, Pahwa R. Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor. Tremor Other Hyperkinet Mov (N Y). 2020 08 14; 10:29. PMID: 32864188.
      View in: PubMed
    19. Sharma P, Sharma SR, Dhall RK, Mittal TC. Effect of ?-radiation on post-harvest storage life and quality of onion bulb under ambient condition. J Food Sci Technol. 2020 Jul; 57(7):2534-2544. PMID: 32549604.
      View in: PubMed
    20. Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C. Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020 02; 71:4-10. PMID: 31927343.
      View in: PubMed
    21. Mirzadeh Z, Chen T, Chapple KM, Lambert M, Karis JP, Dhall R, Ponce FA. Procedural Variables Influencing Stereotactic Accuracy and Efficiency in Deep Brain Stimulation Surgery. Oper Neurosurg (Hagerstown). 2019 07 01; 17(1):70-78. PMID: 30339204.
      View in: PubMed
    22. Pahwa R, Dhall R, Ostrem J, Gwinn R, Lyons K, Ro S, Dietiker C, Luthra N, Chidester P, Hamner S, Ross E, Delp S. An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor. Neuromodulation. 2019 Jul; 22(5):537-545. PMID: 30701655.
      View in: PubMed
    23. Santiago A, Langston JW, Gandhy R, Dhall R, Brillman S, Rees L, Barlow C. Qualitative Evaluation of the Personal KinetiGraphTM Movement Recording System in a Parkinson's Clinic. J Parkinsons Dis. 2019; 9(1):207-219. PMID: 30412506.
      View in: PubMed
    24. Morgan JC, Dhall R, Rubens R, Khanna S, Gupta S. Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations. Parkinsons Dis. 2018; 2018:9763057. PMID: 30425824.
      View in: PubMed
    25. Chen T, Mirzadeh Z, Chapple KM, Lambert M, Shill HA, Moguel-Cobos G, Tr?ster AI, Dhall R, Ponce FA. Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease. J Neurosurg. 2018 03 16; 130(1):109-120. PMID: 29547091.
      View in: PubMed
    26. Lieberman A, Deep A, Shi J, Dhall R, Shafer S, Moguel-Cobos G, Dhillon R, Frames CW, McCauley M. Downward finger displacement distinguishes Parkinson disease dementia from Alzheimer disease. Int J Neurosci. 2018 Feb; 128(2):151-154. PMID: 28911255.
      View in: PubMed
    27. Leehey M, Luo S, Sharma S, Wills AA, Bainbridge JL, Wong PS, Simon DK, Schneider J, Zhang Y, P?rez A, Dhall R, Christine CW, Singer C, Cambi F, Boyd JT. Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. Neurology. 2017 Oct 24; 89(17):1789-1794. PMID: 28972194.
      View in: PubMed
    28. Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017 Sep 12; 89(11):1152-1161. PMID: 28814455.
      View in: PubMed
    29. Ho AL, Ali R, Connolly ID, Henderson JM, Dhall R, Stein SC, Halpern CH. Awake versus asleep deep brain stimulation for Parkinson's disease: a critical comparison and meta-analysis. J Neurol Neurosurg Psychiatry. 2018 07; 89(7):687-691. PMID: 28250028.
      View in: PubMed
    30. Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, Agarwal P, Dhall R, Ondo WG, Klos KJ, Silver DE. Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy. Neurol Clin Pract. 2017 Feb; 7(1):86-93. PMID: 28243505.
      View in: PubMed
    31. Hauser RA, Li R, P?rez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An?Analysis?of?NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127. PMID: 27911341.
      View in: PubMed
    32. Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 05; 316(1):40-50. PMID: 27380342.
      View in: PubMed
    33. Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016 Apr 05; 86(14 Suppl 1):S13-24. PMID: 27044646.
      View in: PubMed
    34. Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemed J E Health. 2016 07; 22(7):590-8. PMID: 26886406.
      View in: PubMed
    35. Chen T, Mirzadeh Z, Chapple K, Lambert M, Dhall R, Ponce FA. "Asleep" deep brain stimulation for essential tremor. J Neurosurg. 2016 Jun; 124(6):1842-9. PMID: 26613177.
      View in: PubMed
    36. Mirzadeh Z, Chapple K, Lambert M, Evidente VG, Mahant P, Ospina MC, Samanta J, Moguel-Cobos G, Salins N, Lieberman A, Tr?ster AI, Dhall R, Ponce FA. Parkinson's disease outcomes after intraoperative CT-guided "asleep" deep brain stimulation in the globus pallidus internus. J Neurosurg. 2016 Apr; 124(4):902-7. PMID: 26452116.
      View in: PubMed
    37. Augustine EF, P?rez A, Dhall R, Umeh CC, Videnovic A, Cambi F, Wills AM, Elm JJ, Zweig RM, Shulman LM, Nance MA, Bainbridge J, Suchowersky O. Sex Differences in Clinical Features of Early, Treated Parkinson's Disease. PLoS One. 2015; 10(7):e0133002. PMID: 26171861.
      View in: PubMed
    38. Bega D, Luo S, Fernandez H, Chou K, Aminoff M, Parashos S, Walker H, Russell DS, Christine CW, Dhall R, Singer C, Bodis-Wollner I, Hamill R, Truong D, Mari Z, Glazmann S, Huang M, Houston E, Simuni T. Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease. Mov Disord Clin Pract. 2015 Dec; 2(4):371-378. PMID: 28393083.
      View in: PubMed
    39. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015 Aug; 14(8):795-803. PMID: 26116315.
      View in: PubMed
    40. Pan D, Dhall R, Lieberman A, Petitti DB. A mobile cloud-based Parkinson's disease assessment system for home-based monitoring. JMIR Mhealth Uhealth. 2015 Mar 26; 3(1):e29. PMID: 25830687.
      View in: PubMed
    41. Lieberman A, Deep A, Dhall R, Tran A, Liu MJ. Early Freezing of Gait: Atypical versus Typical Parkinson Disorders. Parkinsons Dis. 2015; 2015:951645. PMID: 25785228.
      View in: PubMed
    42. Fang JY, P?rez A, Christine CW, Leehey M, Aminoff MJ, Boyd JT, Morgan JC, Dhall R, Nicholas AP, Bodis-Wollner I, Zweig RM, Goudreau JL. Parkinson's disease severity and use of dopaminergic medications. Parkinsonism Relat Disord. 2015 Mar; 21(3):297-9. PMID: 25541182.
      View in: PubMed
    43. Umeh CC, P?rez A, Augustine EF, Dhall R, Dewey RB, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O. No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial. PLoS One. 2014; 9(12):e112287. PMID: 25486269.
      View in: PubMed
    44. Mirzadeh Z, Chapple K, Lambert M, Dhall R, Ponce FA. Validation of CT-MRI fusion for intraoperative assessment of stereotactic accuracy in DBS surgery. Mov Disord. 2014 Dec; 29(14):1788-95. PMID: 25377213.
      View in: PubMed
    45. Lieberman A, Dhall R, Salins N, Sadreddin A, Moguel-Cobos G, Karis J, Krishnamurthi N. Finger displacement in Parkinson disease: up? down? sideways? Int J Neurosci. 2014 May; 124(5):339-43. PMID: 24053160.
      View in: PubMed
    46. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 08; 383(9916):533-40. PMID: 24183563.
      View in: PubMed
    47. Lieberman A, Dhall R, Dhanani S, Salins N, Sadreddin A, Moguel-Cobos G, Pan D, Santiago A, Prigatano G, Krishnamurthi N, Troster A. Distinguishing the tremor of Parkinson's disease from essential tremor: finger displacement. Int J Neurosci. 2014 Mar; 124(3):175-80. PMID: 23879402.
      View in: PubMed
    48. Elm JJ. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012 Oct; 27(12):1513-21. PMID: 23079770.
      View in: PubMed
    49. Lieberman A, Krishnamurthi N, Dhall R, Santiago A, Moguel-Cobos G, Sadreddin A, Husain S, Salins N, Pan D. A simple question about falls to distinguish balance and gait difficulties in Parkinson's disease. Int J Neurosci. 2012 Dec; 122(12):710-5. PMID: 22784291.
      View in: PubMed
    50. Oh SJ, Dhall R, Young A, Morgan MB, Lu L, Claussen GC. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008 Sep; 38(3):1101-7. PMID: 18720508.
      View in: PubMed
    Dhall's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (131) concept(s)
    _
    Co-Authors Expand Description
    See all (2) people
    _
    Similar People Expand Description
    See all (32) people
    _
    Same Department Expand Description
    Search Department